P
Philip L Tzou
Researcher at Stanford University
Publications - 22
Citations - 1009
Philip L Tzou is an academic researcher from Stanford University. The author has contributed to research in topics: Medicine & Mutation. The author has an hindex of 9, co-authored 17 publications receiving 194 citations.
Papers
More filters
Journal ArticleDOI
The biological and clinical significance of emerging SARS-CoV-2 variants.
Kaiming Tao,Philip L Tzou,Janin Nouhin,Ravindra K. Gupta,Tulio de Oliveira,Sergei L Kosakovsky Pond,Daniela Fera,Robert W. Shafer +7 more
TL;DR: The emergence of SARS-CoV-2 variants with novel spike protein mutations that are influencing the epidemiological and clinical aspects of the COVID-19 pandemic has been witnessed as mentioned in this paper.
Journal ArticleDOI
A systematic review of the genetic mechanisms of dolutegravir resistance.
Soo-Yon Rhee,Philip M. Grant,Philip L Tzou,G Barrow,P. Richard Harrigan,John P. A. Ioannidis,Robert W. Shafer +6 more
TL;DR: DoluteGravir monotherapy in virologically suppressed persons and functional dolutegravirmonotherapy in persons with active viral replication were associated with a non-trivial risk of VF plus INSTI resistance mutations.
Journal ArticleDOI
Comparison of an In Vitro Diagnostic Next-Generation Sequencing Assay with Sanger Sequencing for HIV-1 Genotypic Resistance Testing.
Philip L Tzou,Ariyaratne Pramila Nuwantha,Vici Varghese,Charlie Lee,Elian Rakhmanaliev,Carolin Villy,Meiqi Yee,Kevin Tan,Gerd Michel,Benjamin A. Pinsky,Robert W. Shafer +10 more
TL;DR: The IVD NGS assay evaluated in this study was highly concordant with Sanger sequencing, and NGS appeared to attain a modestly increased sensitivity for detecting low-frequency DRMs without compromising sequence accuracy.
Journal ArticleDOI
Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds.
Philip L Tzou,Kaiming Tao,Janin Nouhin,Soo-Yon Rhee,Benjamin D Hu,Shruti Pai,Neil Parkin,Robert W. Shafer +7 more
TL;DR: The CoV-RDB facilitates comparisons between different candidate antiviral compounds, thereby helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development.
Journal ArticleDOI
Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis
TL;DR: The marked loss of activity of many MAbs against Omicron variants underscores the importance of developing MAbs that target conserved regions of spike, and a need for improved MAb susceptibility test standardization or interassay calibration.